Nanolive is attending the ELRIG Drug Discovery 2023 Conference October 18 – 19 in Liverpool, UK

Presentation

Nanolive is delighted to invite you to attend our upcoming presentation at the ELRIG Drug Discovery 2023 Conference in Liverpool on October 18, 2023, from 16:15 to 16:30 in Auditorium 1. During our talk, “A powerful solution for high content label-free live cell imaging and phenotypic screening” we will discuss how high-resolution images analysed using machine learning can provide unbiased information on a range of cellular phenotypic responses to drug treatments. Case studies presented will cover applications including cell viability, immuno-oncology, cell metabolism, and drug selectivity.

Abstract

Speaker: Hope Amos, Scientific Communication Specialist Nanolive.

Get to know the newest label-free imaging platform from Nanolive and explore the possibilities of high content live cell imaging in a 96-well plate.

Digital holotomography is an innovative imaging technique which combines a rotating light source and the intrinsic refractive properties of cellular structures to produce crystal-clear, high resolution (200 nm) images of cells and their organelles, without labels or damage. The newest Nanolive imaging platform- the 3D Cell Explorer 96focus is equipped with a laser-based autofocus and automated stage, to bring high-resolution cell imaging to a completely new scale.

We will showcase how such rich image data can be captured and processed with our AI-powered analysis modules to build a high content drug screening pipeline. We can screen drug mechanism and functionality using different cytotoxicity, fluorescence, and metabolic parameters to select the drug with the best chance of success in vivo. The 3D Cell Explorer 96focus enables the collection of data from different drugs and conditions with replicates, in a single imaging session.

Visit our booth!

We are excited to inform you that Nanolive will be showcasing our latest innovations at Booth H8, on October 18 & 19.

Come and visit us!

Read our latest news

Subscribe to our newsletter

  • This field is for validation purposes and should be left unchanged.